Publication | Open Access

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

Hematological MalignancyAntifibrotic TherapyOncologyMulticentre StudyHematologyPharmacologyPharmacotherapyPhase 2MedicineMyeloid Neoplasia